About this book
Based on the most novel approaches and cutting-edge clinical and scientific information regarding radionuclide imaging and therapies for neuroendocrine tumors, this clinical guidebook represents a unique collaborative effort between endocrinologists, nuclear physicians, oncologists, surgeons, physicists, radio-pharmacists and geneticists. It begins with the embryology, classification and molecular genetics of gastroenteropancreatic neuroendocrine tumors and carcinoids, chromaffin cell tumors, and MEN1- and MEN2-related tumors. Following a chapter on radiopharmaceuticals in neuroendocrine imaging, it turns to the physics and technology of current and cutting-edge radiology, including SPECT/CT and PET/CT and PET/MR. Discussing of radionuclide imaging covers the tumors mentioned above, as well as pulmonary and thymic neuroendocrine tumors and medullary thyroid carcinoma. A presentation of radionuclide therapies follows, including 131I-MIBG therapy, somatostatin receptor-based therapy, and alpha radionuclide therapy, as well as the role of nanoparticles.
Comprehensive and up-to-date, Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors will assist and guide physicians who encounter patients with these conditions, either from a diagnostic or therapeutic standpoint, and particularly emphasizes the current and emerging medical devices and imaging and therapeutic options.
Carcinoid tumor Chromaffin cell tumor Neuroendocrine tumor Radionuclide imaging Radionuclide therapy Pheochromocytoma Paraganglioma MEN1-related tumor MEN2-related tumor Neuroblastoma Gastroenteropancreatic tumor Internal dosimetry Medullary thyroid carcinoma 131I-MIBG therapy Nanoparticles
Editors and affiliations
- DOI https://doi.org/10.1007/978-3-319-46038-3
- Copyright Information Springer International Publishing Switzerland 2017
- Publisher Name Humana Press, Cham
- eBook Packages Medicine
- Print ISBN 978-3-319-46036-9
- Online ISBN 978-3-319-46038-3
- Buy this book on publisher's site